Prevalence and characteristics of post-acute sequelae of SARS-CoV-2 (PASC) in non-hospitalized persons with COVID-19 enrolled in a clinical trial of early treatment (ACTIV-2)

Evering, T. H.; Sanusi, B.; Jilg, N.; Yeh, E.; Moser, C.; Ritz, J.; Wohl, D.; Daar, E. S.; Klekotka, P.; Javan, A. C.; Eron, J. J.; Currier, J.; Hughes, M.; Smith, D.; Chew, K. W.; Investigat, Activ- A. Study Team

Evering, T. H.; Sanusi, B.; Jilg, N.; Yeh, E.; Moser, C.; Ritz, J.; Wohl, D.; Daar, E. S.; Klekotka, P.; Javan, A. C.; Eron, J. J.; Currier, J.; Hughes, M.; Smith, D.; Chew, K. W.; Investigat, Activ- A. Study Team.

Antiviral Therapy ; 26:8-8, 2021.

Article in English | Web of Science | ID: covidwho-1628075

Keywords

Infectious, Diseases; Pharmacology, &, Pharmacy; Virology

Search on Google

XML

Collection: Databases of international organizations Database: Web of Science Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Language: English Journal: Antiviral Therapy Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML